Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis
-
By
-
Shrila Banerjee
-
Abul Kalam Azad Mandal
-
June 11, 2026
-
Clinical Scorecard: Epigallocatechin-3-gallate Inhibits Breast Cancer Development Through the miR-27a/Wnt/β-catenin Signaling Pathway
At a Glance
| Category | Detail |
|---|
| Condition | Breast Cancer |
| Key Mechanisms | miR-27a/Wnt/β-catenin signaling pathway |
| Target Population | Patients with breast cancer, particularly triple-negative breast cancer (TNBC) |
| Care Setting | Oncology |
Key Highlights
- EGCG decreases cell viability and migration in breast cancer cells.
- EGCG induces apoptosis and G0/G1 cell cycle arrest.
- EGCG modulates oncogenic miR-27a-3p expression.
- EGCG affects key Wnt/β-catenin pathway markers, including cyclin-D1.
Guideline-Based Recommendations
Diagnosis
- Consider miR-27a as a potential biomarker for breast cancer diagnosis.
Management
Monitoring & Follow-up
- Monitor miR-27a-3p levels as a potential indicator of treatment response.
Risks
- Evaluate the potential for chemoresistance in breast cancer patients.
Patient & Prescribing Data
Patients with breast cancer, especially those with chemoresistance.
Clinical Best Practices
Related Resources & Content
